Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021, interpretation and expectation
10.3760/cma.j.cn121430-20211009-01442
- VernacularTitle:《拯救脓毒症运动：脓毒症与感染性休克治疗国际指南2021版》解读与展望
- Author:
Ruiqiang ZHENG
1
;
Yifen ZHANG
;
Ziqi RONG
;
Wei HUANG
;
Xiaoyun FU
Author Information
1. 江苏省苏北人民医院重症医学科，江苏扬州 225001
- Keywords:
Critical care medicine;
Critical care;
Guideline;
Sepsis;
Septic shock
- From:
Chinese Critical Care Medicine
2021;33(10):1153-1158
- CountryChina
- Language:Chinese
-
Abstract:
The Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021 (2021 guideline) was recently released. The guidelines summarized the evidences from literatures through to July 2019, and composed by 6 parts as "screening and early treatment", "infection", "hemodynamic management", "ventilation", "additional therapies" and "long-term outcomes and goals of care" with a total of 93 items and 99 recommendations. Compared with the 2016 guideline (96 recommendations), although the total number of recommendations in the 2021 guideline is similar, the number of "strong recommendations (recommend)" in 2021 guideline has dropped significantly, while as the number of "weak recommendations (suggest)" has increased significantly, and the level of the quality of evidence on which the recommendations are based has been significantly lowered. Furthermore, 2021 guideline has also markedly deleted or simplified the recommendations regarding infection prevention, acute respiratory distress syndrome (ARDS) treatment, nutritional support and so on. While, the most obvious improvement appears in the segment of "long-term outcomes and goals of care", in which the patients and their families could get help in term of determining their physical rehabilitation and discharge follow-up plans and formulating exact goals of care. 2021 guideline did not adopt new and emerging therapies or treatments, such as metagenomic next-generation sequencing (mNGS), diaphragm protective ventilation, timing of initiating renal replacement therapy for acute kidney injury, early mobility, endotoxin adsorption, tranexamic acid, E-medicine and telemedicine, big data & artificial intelligence and other new therapies. Collectively, it may suggest the 2021 guideline tend to be conservative and simplified rather than fairly optimized and logicalized, which may arouse controversy in the future and affect clinician compliance.
